NASDAQ:MIST
Milestone Pharmaceuticals Inc. Stock News
$1.69
+0.0500 (+3.05%)
At Close: May 03, 2024
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innova
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
11:26am, Tuesday, 16'th Jan 2024
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street anal
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
12:47pm, Wednesday, 27'th Dec 2023
Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.
Milestone Pharmaceuticals: Worthy Of A Dart Throw
02:37pm, Monday, 22'nd May 2023
Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel delivery system and should have an NDA submitted ar
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
01:33pm, Monday, 16'th Jan 2023
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
11:17am, Tuesday, 13'th Dec 2022
The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
01:33pm, Monday, 14'th Nov 2022
Analysts say these are penny stocks to buy. Do you agree?
Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023
02:28am, Saturday, 05'th Nov 2022
Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. It is said that there are about 2 million PSVT pati
Milestone Pharmaceuticals: Looking Attractive After Drop On Positive News
07:25am, Sunday, 30'th Oct 2022
Milestone Pharmaceuticals reported positive data from the RAPID arm of its pivotal trial. After an initial premarket spurt, the stock dropped drastically.
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks
11:19am, Thursday, 20'th Oct 2022
Milestone Pharmaceuticals (MIST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
07:34pm, Tuesday, 18'th Oct 2022
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp
Head-To-Head Review: ABVC BioPharma (OTCMKTS:ABVC) & Milestone Pharmaceuticals (NASDAQ:MIST)
06:02am, Tuesday, 14'th Dec 2021 Dakota Financial News
ABVC BioPharma (OTCMKTS:ABVC) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk ABVC BioPharma has a beta of 0.55, indicating that its stock price […]
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Position Trimmed by Renaissance Technologies LLC
09:26am, Tuesday, 23'rd Nov 2021 Transcript Daily
Renaissance Technologies LLC trimmed its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 50.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,554 shares of the companys stock after selling 108,846 shares during the period. Renaissance Technologies LLC owned about 0.36% of Milestone []
Milestone Pharmaceuticals (NASDAQ:MIST) Lifted to Hold at Zacks Investment Research
06:52am, Monday, 22'nd Nov 2021 Transcript Daily
Zacks Investment Research upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports. According to Zacks, Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular []
Oppenheimer Research Analysts Increase Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
07:52am, Saturday, 20'th Nov 2021 Dakota Financial News
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Equities researchers at Oppenheimer boosted their FY2021 earnings estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Monday, November 15th. Oppenheimer analyst L. Gershell now forecasts that the company will post earnings of ($1.00) per share for the year, up from their previous estimate of []